| HOME >> BIOLOGY >> TECHNOLOGY |
New Date for Anticipated VentriPoint Diagnostic System Launch, Alpha
Testing Commencement Highlight Management Discussion and Analysis
SEATTLE, Aug. 29 /PRNewswire-FirstCall/ -- VentriPoint Diagnostics (TSX: VPT) today announced that it has filed its management discussion and analysis (MD&A), as well as its unaudited financial results for the three months ended June 30, 2008, with the Canadian Securities Administrators through the SEDAR filing system.
Development Highlights
In its MD&A, VentriPoint describes that because of the recent accomplishments by its development team, the commercial product release of the VentriPoint Diagnostic System is now anticipated to commence in January 2009 instead of March 2009 as previously expected. Other recent milestones include the approval and commencement of alpha testing, transition of the Knowledge Reconstruction Database to its commercial and secure off-site facility, and initiation of the design and production of the product training guide and user's manual.
"Our team has been working diligently to bring the VentriPoint Diagnostic System to market to offer accurate heart measurements in a rapid and inexpensive manner that is not currently available," said Joseph Ashley, CEO of VentriPoint Diagnostics. "We have commenced in-house alpha testing, and we look forward to shipping our units for beta testing in October."
Financial Highlights
In its unaudited financial results, VentriPoint reported a consolidated net loss of $1,062,182 for the three months ended June 30, 2008, or $0.03 per share, compared to a net loss of $193,038, or $0.02 per share for the three months ended June 30, 2007. The increase in net loss is attributed to planned expenditures to accelerate the development of the VentriPoint Diagnostic System.
For the three months ended June 30, 2008, research and development
expenses totaled $651,276, compared to $143,563 for the three months ended
June 30, 2
'/>"/>
| SOURCE VentriPoint Diagnostics Copyright©2008 PR Newswire. All rights reserved |